Abbisko Therapeutics Co. Ltd. on Wednesday entered into a strategic collaboration with AstraZeneca Plc AZN to jointly develop ...
When Jeanne Szurek, 69, was diagnosed with stage IV epidermal growth factor receptor (EGFR)-positive lung cancer in 2024, she wondered if her two adult children were at a higher risk of developing the ...
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted ...
The likelihood of EGFR-positive lung cancer returning is largely tied to how advanced it is when first diagnosed, with lower chances in early stages and higher odds in later stages. Newer targeted ...
Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company") announced that translational research results on its ...
At its December meeting, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use adopted a positive opinion for Aumseqa (aumolertinib mesylate, SFL Pharmaceuticals ...
Patients with stage 4 lung cancer and EGFR mutations may benefit from combination therapies that improve disease control. The American Society of Clinical Oncology (ASCO) released updated treatment ...
Managing stress is crucial when you have EGFR-positive lung cancer, as chronic stress can negatively impact your body’s immune system and contribute to cancer growth and treatment resistance. Stress ...
Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT A multiplex QIF assay was optimized on tissue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results